Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2021-03-02 Major Shareholding Noti…
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding and voting rights for a specific holder ('Redmile Group, LLC') in the issuer ('BioInvent International Aktiebolag'). It explicitly shows the 'Before the transaction' and 'After the transaction' holdings, including the resulting percentage (6.71492%) and the number of shares (2,834,399). This structure is characteristic of a notification regarding a change in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2021-03-02 English
BioInvent och Transgene har rekryterat den första patienten i en fas I/IIa-studie av det nya onkolytiska viruset BT-001 för behandling av solida tumörer
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESSMEDDELANDE" (Press Release) dated March 1, 2021. It announces a specific corporate and clinical development event: the recruitment of the first patient in a Phase I/IIa clinical trial for a new oncolytic virus (BT-001) developed by BioInvent and Transgene. This type of announcement, detailing operational progress, clinical milestones, and partnership updates, is characteristic of an Earnings Release (ER) if it were focused purely on financial results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific operational category. Since it is a major operational update announcing a clinical milestone, and it is not a full financial report (10-K, IR), a management discussion (MDA), or a formal proxy/dividend notice, it fits best as a general regulatory/corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standardized corporate news releases that aren't explicitly defined elsewhere (like M&A, Director Dealing, or Capital Changes). It is not an Earnings Release (ER) as it focuses on clinical progress, not financial performance highlights. It is not an RPA because it is the substantive announcement itself, not just an announcement *about* the publication of another document.
2021-03-01 Swedish
BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" dated March 1, 2021. It announces a specific corporate event: the enrollment of the first patient in a Phase I/IIa clinical trial for a drug candidate (BT-001) developed through a collaboration between BioInvent and Transgene. This type of announcement, detailing operational progress, clinical milestones, and collaboration updates, is characteristic of an Earnings Release (ER) if it were summarizing financial results, or more generally, a Regulatory Filing (RNS) if it's a broad operational update not covered by other specific codes. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change, and it is a formal announcement of a significant operational/clinical milestone, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for important, non-standard announcements. It is not an Earnings Release (ER) as it contains no financial performance data, nor is it a Report Publication Announcement (RPA) as it is the news itself, not an announcement *about* another report being published.
2021-03-01 English
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a 'Change in the number of shares and votes' due to a directed share issue. This directly relates to a change in the company's capital structure through the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). The document is short and provides the final figures resulting from the capital change, not just an announcement of an upcoming report.
2021-02-26 English
Ändring av antalet aktier och röster i BioInvent International AB
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement dated February 26, 2021, titled "Ändring av antalet aktier och röster i BioInvent International AB" (Change in the number of shares and votes in BioInvent International AB). It explicitly states the new total number of shares (42,210,495) resulting from a directed share issue. This directly relates to a change in the company's capital structure via the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a general regulatory filing (RNS) because it fits a specific category, nor is it an announcement of a report (RPA).
2021-02-26 Swedish
Earnings Release 2020
Earnings Release Classification · 99% confidence The document contains detailed financial figures for the Fourth Quarter of 2020 and the full year 2020, including revenue, net income, and cash flow. It also includes a CEO's commentary and a detailed pipeline update, which are characteristic features of a periodic financial report. Since the report covers a full year (January - December 2020) and includes comprehensive financial statements (even if summarized), it strongly suggests an Annual Report or a comprehensive period report. However, the structure, focusing heavily on Q4 results and year-end figures, combined with significant operational updates, aligns best with a comprehensive periodic report. Given the inclusion of full-year results and detailed financial metrics, it is more comprehensive than a simple Earnings Release (ER). Since it covers the full fiscal year, it is most likely an Annual Report (10-K) or a very detailed Interim Report (IR). Since the text explicitly details results for 'Januari – december 2020' (Full Year 2020), the most appropriate classification among the options that cover comprehensive financial results is the Annual Report (10-K), although in a non-US context, it might be an Annual Report (AR) or a very detailed Q4 report. Given the comprehensive nature covering the full year, 10-K is the closest fit for a major annual filing, even if it's presented in a non-SEC format. If it were only Q4, IR would be a strong candidate, but the inclusion of the full year makes 10-K the best fit for a comprehensive annual review. Q4 2020
2021-02-23 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.